Striverdi Respimat

Report
16 Pages
July 2018
Region: Global
Citeline
ID: 4775191

Drug Overview
Striverdi (olodaterol; Boehringer Ingelheim) is a long-acting beta 2 agonist delivered via the Respimat inhaler. It is indicated for the once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Striverdi Respimat received US and EU approvals for use in COPD in July 2014 and October 2013, respectively. The author is not aware of any specific development of olodaterol monotherapy in Japan and does not forecast the therapy for this market.

OVERVIEW

Drug Overview
Product Profiles
Striverdi Respimat: Chronic obstructive pulmonary disease (COPD)

LIST OF FIGURES

Figure 1: Striverdi Respimat for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 3: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 4: Striverdi Respimat sales for COPD across the US and five major EU markets, by country, 2017–26

LIST OF TABLES

Table 1: Striverdi Respimat drug profile
Table 2: Striverdi Respimat Phase III data in COPD
Table 3: Striverdi Respimat sales for COPD across the US and five major EU markets, by country ($m), 2017–26

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9652EUR$10,000USD£8,279GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47295EUR$49,000USD£40,569GBP

Table of Contents

Related Topics

Related Reports

Anti-Asthmatics and COPD Drugs Global Market Report 2024

Pulmonary Drugs - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024

Pulmonary / Respiratory Drug Delivery - Global Strategic Business Report